Business News • PR NewsWire • Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia

Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia

Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia

Data Demonstrating a 35% Overall Response Rate with a Median Progression-Free Survival of 12.6 Months in Patients with Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia to be Published in the February 1, 2010 Issue of the Journal of Clinical Cancer Research QUÉBEC CITY, Jan. 29 /

View More : http://www.prnewswire.com/news-releases/aeterna-zentaris-partner-keryx-announces-positive-phase-2-results-for-perifosine...

Releted News by prnewswire

NetDragon Wins Four Awards at 2009 China Game Industry Annual Conference

Leading IT Training Firm K Alliance Sponsors Training 2010 Conference & Expo

3D Eye Solutions, Inc. Signs License Agreement with Artfest International, Inc. Bringing 3-D Technology to Fine Arts and Sports Memorabilia Industry